Journal article

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial

AC Keech, P Mitchell, PA Summonen, J O'Day, TME Davis, MS Moffitt, MR Taskinen, RJ Simes, D Tse, E Williamson, A Merrifield, LT Laatikainen, MC d'Emden, DC Crimet, RL O'Connell, PG Colman

The Lancet | ELSEVIER SCIENCE INC | Published : 2007


BACKGROUND: Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus. METHODS: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a multinational randomised trial of 9795 patients aged 50-75 years with type 2 diabetes mellitus. Eligible patients were randomly assigned to receive fenofibrate 200 mg/day (n=4895) or matching placebo (n=4900). At each clinic visit, information concerning laser treatment for diab..

View full abstract